- Home
- OSS vs BIVI Comparison
OSS vs BIVI Comparison
Compare OSS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OSS | BIVI |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.7M | 10.3M |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OSS | BIVI |
|---|---|---|
| Price | $9.16 | $1.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 642.6K | 460.1K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.85 | 74.83 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,027,382.00 | N/A |
| Revenue This Year | $22.19 | N/A |
| Revenue Next Year | $20.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.46 | N/A |
| 52 Week Low | $4.17 | $0.82 |
| 52 Week High | $20.88 | $3.79 |
Technical Indicators
Market Signals| Indicator | OSS | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 40.18 | N/A |
| Support Level | $8.03 | N/A |
| Resistance Level | $10.74 | N/A |
| Average True Range (ATR) | 0.39 | 0.00 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 55.21 | 0.00 |
Price Performance
Historical ComparisonAbout OSS One Stop Systems Inc.
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.